Atossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast Cancer

About this update from Atossa Therapeutics, Inc.

Event to feature Dr. Laura Esserman, internationally recognized surgical oncologist, breast cancer expert, and founder and principal investigator of the I-SPY Trials SEATTLE, May 14, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of significant unmet medical need, today announced that it will host a virtual key opinion leader event focused on the evolving clinical and translational data supporting the development of (Z)-endoxifen, the Company's investigational selective estrogen receptor modulator/degrader, or SERM/D, as a potential next-generation endocrine therapy backbone across multiple estrogen receptor ("ER") -positive breast cancer settings. The event will feature internationally recognized surgical oncologist and breast cancer expert Dr. Laura Esserman. Dr. Esserman serves as Director of the University of California San Francisco Breast Care Center and is the founder and principal investigator of the I-SPY Trials, an innovative platform designed to accelerate the development of personalized breast cancer therapies. "Dr. Esserman has been at the forefront of innovation in breast cancer clinical research, adaptive trial design, and precision oncology for decades," said Dr. Steven Quay, M.D., Ph.D., Chairman and Chief Executive Officer of Atossa Therapeutics. "We believe (Z)-endoxifen has the potential to become more than a single-indication therapy; it may serve as an endocrine therapy platform across multiple ER-positive breast cancer settings. Dr. Esserman's leadership in translational breast cancer research makes her an ideal expert to discuss the emerging clinical and biomarker data supporting this opportunity." The discussion is expected to address several topics of interest to clinicians, investors, and potential strategic partners, including: Event Details Date: Tuesday, May 19, 2026Time: 1:00 to 2:00 p.m. PTModerator: Michael King, Managing Director at Rodman & RenshawRegistration: https://zoom.us/webinar/register/WN_fd6jdLUvQPC-3J84CUEnMA Attendees may submit questions to [email protected] up to 24 hours prior to the event. A replay of the webcast will be available on the Company's "Investors" portion of its website for at le...

View stock analysis, news, and events for Atossa Therapeutics, Inc.